Cell sources for cardiovascular tissue regeneration and engineering
- PMID: 19241306
- DOI: 10.1055/s-2008-1039235
Cell sources for cardiovascular tissue regeneration and engineering
Abstract
The heart has long been regarded as a post-mitotic organ. Since many years, physicians have focused on developing strategies to restore the myocardium after ischemic damage followed by ventricular dysfunction. Restoration is generally achieved through the redirection of blood flow or by supporting contractile performance. The discovery of stem cells capable of generating angiogenic or contractile cells and structures offers new horizons to patients suffering from myocardial disease. Experimental studies indicate that the delivery or mobilization of stem and progenitor cells may improve tissue perfusion and the contractile performance of the damaged heart. Another aspect of restoration is based on cardiovascular tissue engineering and the creation of three-dimensional biological conformations to replace the artificial materials frequently used during operations, i.e., valves and grafts, or even a portion of the nonfunctional myocardial tissue. At present, the underlying intra- and intercellular molecular mechanisms controlling myocardiogenesis and cardiomyocyte replacement during regenerative processes are not very well understood. In this brief review we try to give the answers to questions on certain aspects of myocardial tissue regeneration and engineering procedures.
Similar articles
-
Stem cell therapy in cardiovascular disorders.Cardiovasc Ther. 2010 Oct;28(5):e101-10. doi: 10.1111/j.1755-5922.2010.00208.x. Cardiovasc Ther. 2010. PMID: 21050418 Review.
-
Myocardial regeneration strategies using human embryonic stem cell-derived cardiomyocytes.J Control Release. 2006 Nov 28;116(2):211-8. doi: 10.1016/j.jconrel.2006.06.027. Epub 2006 Jun 29. J Control Release. 2006. PMID: 17005287 Review.
-
Endogenous cardiac stem cells.Prog Cardiovasc Dis. 2007 Jul-Aug;50(1):31-48. doi: 10.1016/j.pcad.2007.03.005. Prog Cardiovasc Dis. 2007. PMID: 17631436 Review.
-
Cellular cardiac regenerative therapy in which patients?Expert Rev Cardiovasc Ther. 2009 Aug;7(8):911-9. doi: 10.1586/erc.09.84. Expert Rev Cardiovasc Ther. 2009. PMID: 19673669 Review.
-
Stem cell therapy after myocardial infarction: ready for clinical application?Curr Opin Mol Ther. 2006 Oct;8(5):396-414. Curr Opin Mol Ther. 2006. PMID: 17078382 Review.
Cited by
-
Scaffold stiffness affects the contractile function of three-dimensional engineered cardiac constructs.Biotechnol Prog. 2010 Sep-Oct;26(5):1382-90. doi: 10.1002/btpr.435. Biotechnol Prog. 2010. PMID: 20945492 Free PMC article.
-
Cardioprotective effects of erythropoietin in diabetic rats determined by CD34 and vascular endothelial growth factor levels.Arch Med Sci Atheroscler Dis. 2020 Jan 19;5:e1-e12. doi: 10.5114/amsad.2020.92346. eCollection 2020. Arch Med Sci Atheroscler Dis. 2020. PMID: 33585719 Free PMC article.
-
Biomimetic perfusion and electrical stimulation applied in concert improved the assembly of engineered cardiac tissue.J Tissue Eng Regen Med. 2012 Nov;6(10):e12-23. doi: 10.1002/term.525. Epub 2011 Dec 13. J Tissue Eng Regen Med. 2012. PMID: 22170772 Free PMC article.
-
Cardiac renewing: interstitial Cajal-like cells nurse cardiomyocyte progenitors in epicardial stem cell niches.J Cell Mol Med. 2009 May;13(5):866-86. doi: 10.1111/j.1582-4934.2009.00758.x. Epub 2009 Apr 20. J Cell Mol Med. 2009. PMID: 19382895 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical